Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Vojnosanit Pregl ; 65(11): 847-50, 2008 Nov.
Article in Serbian | MEDLINE | ID: mdl-19069718

ABSTRACT

BACKGROUND: Ebstein's anomaly is characterized by a displacement of the tricuspid valve toward apex, because of anomalous attachment of the tricuspid leaflets. There are type B of Wolff-Parkinson-White (WPW) syndrome and paroxysmal arrhythmias in more than a half of all patients. CASE REPORT: We presented a female, 32-year old, with frequent paroxysms of atrial fibrillation. After conversion of rhythm an ECG showed WPW syndrome. Echocardiographic examination discovered normal size of the left cardiac chambers with paradoxical ventricular septal motion. The right ventricle was very small because of its atrialization. The origin of the tricuspid valve was 20 mm closer to apex of the right ventricle than the origin of the mitral valve. Electrophysiological examination showed a posterolateral right accesorial pathway. Atrial fibrillation was induced very easily in electrophysiological laboratory and a successful ablation of accessorial pathway was made. There were no WPW syndrome and paroxysms of atrial fibrillation after that. CONCLUSION: Ebstein's anomaly is one of the reasons of paroxysmal atrial fibrillation, especially in young persons with WPW syndrome.


Subject(s)
Atrial Fibrillation/etiology , Ebstein Anomaly/complications , Adult , Ebstein Anomaly/pathology , Ebstein Anomaly/physiopathology , Electrocardiography , Female , Humans , Wolff-Parkinson-White Syndrome/etiology
2.
Kardiol Pol ; 66(11): 1207-9, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19105099

ABSTRACT

Rhabdomyosarcoma accounts for 20% of primary malignant cardiac tumours. We describe a woman with cardiac rhabdomyosarcoma. She had loss of appetite, loss of weight, and symptoms of heart failure. A mobile tumour in the left atrium, entering the left ventricle during diastole, was detected by transthoracic echocardiography. The tumour was removed surgically in total; histological diagnosis was rhabdomyosarcoma; however, the patient died after 6 months. In conclusion, primary malignant cardiac tumours can simulate heart failure or systemic disorders. Cardiac rhabdomyosarcomas have a poor prognosis with average survival of 6 months after diagnosis.


Subject(s)
Heart Failure/etiology , Heart Neoplasms/complications , Rhabdomyosarcoma/complications , Aged , Fatal Outcome , Female , Heart Neoplasms/pathology , Humans , Rhabdomyosarcoma/pathology
3.
Vojnosanit Pregl ; 64(5): 353-6, 2007 May.
Article in Serbian | MEDLINE | ID: mdl-17585553

ABSTRACT

BACKGROUND: Primary malignant cardiac tumors are rare entities and rhabdomyosarcoma accounts 20% of these lesions. CASE REPORT: We presented a female patient with loss of appetite and loss of weight. She also had symptoms of heart failure and bilateral pleural effusions. A mobile tumor in the left heart with the entrance from the left atrium to left ventricle during diastole was seen by transthoracic echocardiography. The tumor was extirpated in total, histologic diagnosis was rhabdomyosarcoma, and the patient died after 6 months. CONCLUSION: Primary malignant cardiac tumors can simulate heart failure or systemic disorders. Cardiac rhabdomyosarcomas have a poor prognosis with the average survival of 6 months after the occurrence of symptoms and making a diagnosis. In cardiac insufficiency, differential diagnostics should be used to consider cardiac tumors that could be with certainty confirmed or excluded by echocardiography.


Subject(s)
Heart Neoplasms/diagnosis , Rhabdomyosarcoma/diagnosis , Aged , Diagnosis, Differential , Female , Humans
4.
Vojnosanit Pregl ; 64(2): 117-21, 2007 Feb.
Article in Serbian | MEDLINE | ID: mdl-17348463

ABSTRACT

BACKGROUND/AIM: Most patients with acute myocardial infarction with ST-segment elevation (STEMI) are still treated with pharmacological reperfusion, which is not always successful. That is the reason for searching possibilities for a better success of reperfusion with adding new antiplatelet drugs. The aim of this study was to investigate weather addition of clopidogrel as a second antiplatelet drug, improves the patency of the infarct-related artery after STEMI. METHODS: We prospectively enrolled 65 patients, 29-72 years old, hospitalized due to the first STEMI within 6 hours after the on-set of a chest pain. They were treated with a fibrinolytic agent (streptokinase or tissue plasminogen activator--tPA), aspirin, and low molecular heparin (enoxaparin). A group of 50 patients, beside this therapy, received clopidogrel. Coronary angiography was performed between 5th and 10th day of hospitalization to assess for late patency of the infarct-related artery. Infarct-related artery was considered as patent if thrombolysis in myocardial infarction (TIMI) flow grade was 2 or 3, and as occluded if TIMI flow grade was 0 or 1. RESULTS: In the group of patients who received double antiplatelet therapy (aspirin and clopidogrel), infarct-related artery was occluded in 3 cases (6%); in the group of patients without clopidogrel, infarct-related artery was occluded in 4 patients (26.7%),p < 0.05. There were less frequency of postinfarction angina (6% vs 13.3%), and rarer necessity for rescue percutaneous coronary intervention (4% vs. 13.3%) in the first group, but without statistical significance. CONCLUSION: Adding of clopidogrel to the standard reperfusion pharmacotherapy, as a second antiplatelet drug, increases the number of patients with patent infarct-related artery and the success of reperfusion.


Subject(s)
Aspirin/administration & dosage , Myocardial Infarction/drug therapy , Platelet Aggregation Inhibitors/administration & dosage , Thrombolytic Therapy , Ticlopidine/analogs & derivatives , Vascular Patency , Adult , Aged , Clopidogrel , Coronary Angiography , Drug Therapy, Combination , Electrocardiography , Female , Fibrinolytic Agents/administration & dosage , Humans , Male , Middle Aged , Myocardial Infarction/physiopathology , Ticlopidine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...